Nature Reviews Clinical Oncology

Papers
(The H4-Index of Nature Reviews Clinical Oncology is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Tasadenoturev active in DIPG1090
A new standard of care for advanced-stage urothelial carcinoma746
From little subclones grow mighty oaks745
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma717
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC629
Hodgkin lymphoma: great progress with room for improvement623
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes595
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC577
Novel ICI–TKI combination improves HCC outcomes565
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care542
The immune landscape of common CNS malignancies: implications for immunotherapy533
Gut microbiota in colorectal cancer development and therapy528
Current understanding and management of CAR T cell-associated toxicities524
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime480
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials480
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety448
The emerging roles of circRNAs in cancer and oncology438
From ESMO 2022437
From the ESMO Congress 2021386
Mortality is similar with active monitoring340
Contrasting results with second-line CAR T cells in large B cell lymphoma337
Ponatinib superior to imatinib in Ph+ ALL337
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence335
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC334
Sacituzumab tirumotecan improves OS in mTNBC328
Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?319
Humanized mouse models for immuno-oncology research313
Minimal residual disease as a target for liquid biopsy in patients with solid tumours300
Predicting cancer outcomes with radiomics and artificial intelligence in radiology285
Harnessing cytokines and chemokines for cancer therapy284
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response277
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours277
Craniospinal irradiation improves leptomeningeal metastasis control257
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs245
Survival benefit with second-line combination in endometrial cancer245
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease244
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer224
Biomarkers for immunotherapy of hepatocellular carcinoma210
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship206
Improving outcomes in patients with oesophageal cancer202
Harnessing big data to characterize immune-related adverse events200
Spatial landscapes of cancers: insights and opportunities199
Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070198
Approvals in 2022: overall survival, dose optimization, new approvals and beyond195
DREAMseq of therapy for BRAF-mutant melanoma195
New CAPSTONE of SCLC therapy?194
Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions191
SHINE a light: frontline ibrutinib for MCL191
Women with clinically node negative breast cancer can safely avoid axillary surgery188
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC188
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC181
Aumolertinib is effective in NSCLC172
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond171
From ESMO 2023: advances in lung cancer166
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer158
Mitigating acute chemotherapy-associated adverse events in patients with cancer158
Circulating tumour DNA — looking beyond the blood151
Targeting chromosomal instability in patients with cancer147
Long-term outcomes following CAR T cell therapy: what we know so far143
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC140
Benefit with ramucirumab in mesothelioma139
Response to neoadjuvant endocrine therapy complements recurrence score134
Multiomics STEP up in correlative analysis of response to CAR T cells131
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress130
From the ESMO Congress 2023129
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM116
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas113
HAIC-FO improves outcomes in HCC113
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma110
Newly approved cancer drugs in China — innovation and clinical benefit109
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL108
Claudin 18.2 as a novel therapeutic target107
Enhancing immunotherapy with tumour-responsive nanomaterials106
Lung cancer in patients who have never smoked — an emerging disease106
Clinical implications of T cell exhaustion for cancer immunotherapy104
From the 2021 ASCO Annual Meeting99
Targeted biopsy reduces detection of clinically insignificant cancer97
HCL — vemurafenib plus rituximab holds promise97
Combining CAR T cells effective in RRMM95
Two decades of advances in clinical oncology — lessons learned and future directions90
Translating biological insights into improved management of endometrial cancer86
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer86
Less-frequent surveillance is noninferior to annual mammography83
0.083451986312866